论文部分内容阅读
目的观察新辅助化疗治疗结肠癌肝转移对患者血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)、糖抗原19-9(CA199)、细胞角质蛋白19片段(CYFRA21-1)水平的影响。方法选择2010年3月-2011年12月我院就诊的112例结肠癌肝转移患者,所有患者均给予新辅助化疗治疗。观察患者在治疗前后血清VEGF、CEA、CA199、CYFRA21-1水平变化。结果 112例患者治疗后血清VEGF、CEA、CA199、CYFRA21-1水平均显著性的低于治疗前(P<0.05)。结论新辅助化疗治疗结肠癌肝转移能有效的降低患者血清VEGF、CEA、CA199、CYFRA21-1水平。
Objective To observe the effects of neoadjuvant chemotherapy on the levels of serum vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA199) and cytokeratin 19 (CYFRA21-1) in patients with colon cancer. . Methods From March 2010 to December 2011, 112 patients with liver metastases from colon cancer treated in our hospital were enrolled. All patients received neoadjuvant chemotherapy. The changes of serum VEGF, CEA, CA199 and CYFRA21-1 in patients before and after treatment were observed. Results The serum levels of VEGF, CEA, CA199 and CYFRA21-1 in 112 patients were significantly lower than those before treatment (P <0.05). Conclusion Neoadjuvant chemotherapy for liver metastases of colon cancer can effectively reduce the serum levels of VEGF, CEA, CA199 and CYFRA21-1.